81 related articles for article (PubMed ID: 36099421)
1. Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.
Ruiz G; Enrico D; Mahmoud YD; Ruiz A; Cantarella MF; Leguina L; Barberis M; Beña A; Brest E; Starapoli S; Mendoza Bertelli A; Tsou F; Pupareli C; Coppola MP; Scocimarro A; Sena S; Levit P; Perfetti A; Aman E; Girotti MR; Arrieta O; Martín C; Salanova R
Thorac Cancer; 2024 Apr; 15(11):895-905. PubMed ID: 38456253
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer.
Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
Cancer Immunol Immunother; 2017 Jul; 66(7):865-876. PubMed ID: 28341875
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological characteristics and tumor infiltrating immune cells associations of PD-L1 tumor expression in non-small cell lung cancer patients.
Aazzane O; Bakhtaoui FZ; Stitou S; Fellah H; Karkouri M
Tunis Med; 2024 Apr; 102(4):223-228. PubMed ID: 38746962
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC.
John N; Schlintl V; Sassmann T; Lindenmann J; Fediuk M; Wurm R; Douschan P; Zacharias M; Kalson L; Posch F; Absenger G; Brcic L; Jost PJ; Terbuch A
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604811
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Robotic Bronchoscopy for Molecular Marker Analysis in Primary Lung Cancer.
Yu Lee-Mateus A; Sawal N; Hartley C; Edell E; Vierkant RA; Reisenauer J
Clin Lung Cancer; 2024 Jan; 25(1):e11-e17. PubMed ID: 37932179
[TBL] [Abstract][Full Text] [Related]
6. Perioperative Immunotherapy in Non-Small Cell Lung Cancer.
O'Brien J; Bodor JN
Curr Treat Options Oncol; 2023 Dec; 24(12):1790-1801. PubMed ID: 38091187
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological characterization of next-generation sequencing detected mutations in lung cancers-a single-center experience.
Walter J; Tufman A; Kumbrink J; Neumann J; Kahnert K; Sellmer L; Jung A; Behr J; Kauffmann-Guerrero D
Transl Lung Cancer Res; 2024 Apr; 13(4):799-810. PubMed ID: 38736491
[TBL] [Abstract][Full Text] [Related]
8. Real-World Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Early-Stage Non-Small-Cell Lung Cancer.
O'Sullivan DE; Boyne DJ; Ford-Sahibzada C; Inskip JA; Smith CJ; Sripada K; Brenner DR; Cheung WY
Curr Oncol; 2024 Jan; 31(1):447-461. PubMed ID: 38248115
[TBL] [Abstract][Full Text] [Related]
9. Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease.
Rangachari D; Costa DB
Transl Cancer Res; 2017 Feb; 6(Suppl 1):S151-S157. PubMed ID: 30613479
[No Abstract] [Full Text] [Related]
10. Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy.
Xu Z; Hao X; Wang Q; Yang K; Li J; Xing P
BMC Cancer; 2023 Mar; 23(1):206. PubMed ID: 36870951
[TBL] [Abstract][Full Text] [Related]
11. EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada.
Sara Kuruvilla M; Liu G; Syed I; Gwadry-Sridhar F; Sheffield BS; Sachdeva R; Pencz A; Zhan L; Hueniken K; Patel D; Balaratnam K; Khan K; Grant B; Noy S; Singh K; Liu L; Rakibuz-Zaman M; Moldaver D; Kate Shanahan M; Cheema PK
Lung Cancer; 2022 Nov; 173():58-66. PubMed ID: 36152478
[TBL] [Abstract][Full Text] [Related]
12. EGFR Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil.
Alves Pinto I; de Oliveira Cavagna R; Virginio da Silva AL; Dias JM; Santana IV; Souza LC; Ferreira da Silva FA; Biazotto Fernandes MF; Junqueira Pinto GD; Negreiros IS; Santiago Gonçalves MF; de Paula FE; Berardinelli GN; Casagrande GMS; Oliveira da Silva M; Albino da Silva EC; de Oliveira MA; Jacinto AA; Duval da Silva V; Reis RM; De Marchi P; Leal LF
Oncologist; 2022 Nov; 27(11):e899-e907. PubMed ID: 36099421
[TBL] [Abstract][Full Text] [Related]
13. Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)-A Single Center, Retrospective Observational Study.
Stephan-Falkenau S; Streubel A; Mairinger T; Kollmeier J; Misch D; Thiel S; Bauer T; Pfannschmidt J; Hollmann M; Wessolly M; Blum TG
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293366
[TBL] [Abstract][Full Text] [Related]
14. Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers.
Liam CK; Yew CY; Pang YK; Wong CK; Poh ME; Tan JL; Soo CI; Loh TC; Chin KK; Munusamy V; Liam YS; Ibrahim NH
BMC Cancer; 2023 Jul; 23(1):659. PubMed ID: 37452277
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer.
Saw SPL; Ng WP; Zhou S; Lai GGY; Tan AC; Ang MK; Lim WT; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Chan JWK; Teh YL; Pang M; Yeo JC; Takano A; Ong BH; Tan EH; Tan SH; Skanderup AJ; Tan DSW
Eur J Cancer; 2023 Jan; 178():139-149. PubMed ID: 36436331
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
[TBL] [Abstract][Full Text] [Related]
17.
Hofman P
Cells; 2021 Aug; 10(8):. PubMed ID: 34440926
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
